CHINAUNITEDVENTUREINVESTMENTLIMITED (IncorporatedintheCaymanIslandsandcontinuedinBermudawithlimitedliability) (于开曼群岛注册成立并于百慕大存续之有限公司) ANNUALREPORT 年报 2022 CHARACTERISTICSOFGEMOFTHESTOCKEXCHANGEOFHONGKONGLIMITED(THE“EXCHANGE”) GEMhasbeenpositionedasamarketdesignedtoaccommodatesmallandmid-sizedcompaniestowhichahigherinvestmentriskmaybeattachedthanothercompanieslistedontheExchange.Prospectiveinvestorsshouldbeawareofthepotentialrisksofinvestinginsuchcompaniesandshouldmakethedecisiontoinvestonlyafterdueandcarefulconsideration. GiventhatthecompanieslistedonGEMaregenerallysmallandmid-sizedcompanies,thereisariskthatsecuritiestradedonGEMmaybemoresusceptibletohighmarketvolatilitythansecuritiestradedontheMainBoardandnoassuranceisgiventhattherewillbealiquidmarketinthesecuritiestradedonGEM. HongKongExchangesandClearingLimitedandtheExchangetakenoresponsibilityforthecontentsofthisreport,makenorepresentationastoitsaccuracyorcompletenessandexpresslydisclaimanyliabilitywhatsoeverforanylosshowsoeverarisingfromorinrelianceuponthewholeoranypartofthecontentsofthisreport. Thisreport,forwhichthedirectors(the“Directors”)ofChinaUnitedVentureInvestmentLimited(formerlyknownasGLORYMARKHI-TECH(HOLDINGS)LIMITED)(the“Company”, togetherwithitssubsidiaries,the“Group”)collectivelyandindividuallyacceptfullresponsibility,includesparticularsgivenincompliancewiththeRulesGoverningtheListingofSecuritiesonGEMoftheExchange(the“GEMListingRules”)forthepurposeofgivinginformationwithregardtotheCompany.TheDirectors,havingmadeallreasonableenquiries,confirmthattothebestoftheirknowledgeandbelief,theinformationcontainedinthisreportisaccurateandcompleteinallmaterialrespectsandnotmisleadingordeceptive,andtherearenoothermatterstheomissionofwhichwouldmakeanystatementhereinorthisreportmisleading. 香港联合交易所有限公司(“联交所”) GEM之特色 GEM之定位乃为相较其他在联交所上市之公司带有更高投资风险之中小型公司提供一个上市之市场。有意投资者应了解投资于该等公司之潜在风险,并应经过审慎周详考虑后方作出投资决定。 由于在GEM上市之公司一般为中小型公司,在GEM买卖之证券可能会较于主板买卖之证券承受更大市场波动风险,同时无法保证在GEM买卖之证券会有高流通量之市场。 香港交易及结算所有限公司及联交所对本报告之内容概不负责,对其准确性或完整性亦不发表任何声明,并明确表示概不就因本报告全部或任何部分内容而产生或因倚赖该等内容而引致的任何损失承担任何责任。 本报告的资料乃遵照联交所GEM证券上市规则 (“GEM上市规则”)而刊载,旨在提供有关新华联合投资有限公司(前称辉煌科技(控股)有限公司)(“本公司”,连同其附属公司,统称 “本集团”)的资料;本公司董事(“董事”)愿就本报告的资料共同及个别地承担全部责任。各董事在作出一切合理查询后,确认就其所深知及确信,本报告所载资料在各重大方面均属准确完备,没有误导或欺诈成份,且并无遗漏其他事项,致令本报告所载任何陈述或本报告产生误导。 ANNUALREPORT2022年报20221 Contents 目录 Pages 页次 CORPORATEINFORMATION3 公司资料 CHAIRMAN’SSTATEMENT6 主席报告书 MANAGEMENTDISCUSSIONANDANALYSIS10 管理层论述及分析 BIOGRAPHICALDETAILSOFDIRECTORSANDSENIORMANAGEMENT23 董事及高级管理人员简历 DIRECTORS’REPORT30 董事会报告 CORPORATEGOVERNANCEREPORT42 企业管治报告 INDEPENDENTAUDITOR’SREPORT62 独立核数师报告 CONSOLIDATEDSTATEMENTOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME70 综合损益及其他全面收益表 CONSOLIDATEDSTATEMENTOFFINANCIALPOSITION72 综合财务状况报表 CONSOLIDATEDSTATEMENTOFCHANGESINEQUITY74 综合权益变动表 CONSOLIDATEDSTATEMENTOFCASHFLOWS76 综合现金流量表 NOTESTOTHECONSOLIDATEDFINANCIALSTATEMENTS79 综合财务报表附注 FINANCIALSUMMARY216 财务概要 2ChinaUnitedVentureInvestmentLimited新华联合投资有限公司 CorporateInformation 公司资料 EXECUTIVEDIRECTORS Mr.WangLiFeng(Vice-Chairman) Mr.FanXiaoling Mr.NiXian(appointedon4March2022) Dr.ChenXiaofeng(appointedon17February2022andresignedon29December2022) Mr.YuSanlong(resignedon29December2022) Ms.LeeJui-lan(resignedon6May2022) Mr.SuGuang(Chiefexecutive)(appointedon1May2022andresignedon29December2022) NON-EXECUTIVEDIRECTOR Mr.HuangBin(Chairman)(appointedon20February2022) INDEPENDENTNON-EXECUTIVEDIRECTORS Dr.YanKaShing Mr.SuiFuxiang(appointedon17August2022) Dr.FongChiWai,Alex(resignedon17August2022)Dr.FengShen(ceasedon4March2022) Mr.WuLebin(appointedon20February2022) Mr.XuLin(appointedon4March2022andresignedon29December2022) COMPANYSECRETARY Mr.ManYunWah(resignedon8April2022) Mr.TamSikWai(appointedon8April2022andresignedon14November2022) Mr.TsangShiaoTung,Joseph(appointedon14November2022) AUTHORISEDREPRESENTATIVES Mr.WangLiFeng Mr.TamSikWai(appointedon8April2022andresignedon14November2022) Mr.TsangShiaoTung,Joseph(appointedon14November2022) COMPLIANCEOFFICER Mr.WangLiFeng 执行董事 王漓峰先生(副主席)范小令先生 倪弦先生(于二零二二年三月四日获委任)陈晓锋博士(于二零二二年二月十七日 获委任及于二零二二年十二月二十九日辞任)于三龙先生(于二零二二年十二月二十九日 辞任) 李瑞兰女士(于二零二二年五月六日辞任)苏光先生(行政总裁)(于二零二二年 五月一日获委任及于二零二二年十二月二十九日辞任) 非执行董事 黄斌先生(主席)(于二零二二年二月二十日获委任) 独立非执行董事 甄嘉胜医生 隋福祥先生(于二零二二年八月十七日获委任)方志伟博士(于二零二二年八月十七日辞任)冯申博士(于二零二二年三月四日卸任) 吴乐斌先生(于二零二二年二月二十日获委任)许琳先生(于二零二二年三月四日获委任及 于二零二二年十二月二十九日辞任) 公司秘书 文润华先生(于二零二二年四月八日辞任)谭式为先生(于二零二二年四月八日获委任及 于二零二二年十一月十四日辞任)曾晓东先生 (于二零二二年十一月十四日获委任) 授权代表 王漓峰先生 谭式为先生(于二零二二年四月八日获委任及于二零二二年十一月十四日辞任) 曾晓东先生(于二零二二年十一月十四日获委任) 监察主任 王漓峰先生 ANNUALREPORT2022年报20223 CorporateInformation 公司资料 AUDITCOMMITTEE Dr.YanKaShing(Chairman) Mr.SuiFuxiang(appointedon17August2022)Dr.FengShen(ceasedon4March2022) Mr.XuLin(appointedon4March2022andresignedon29December2022) Dr.FongChiWai,Alex(resignedon17August2022) REMUNERATIONCOMMITTEE Dr.YanKaShing(Chairman) Mr.SuiFuxiang(appointedon17August2022)Mr.WangLiFeng Dr.FengShen(ceasedon4March2022) Dr.FongChiWai,Alex(appointedon4March2022andresignedon17August2022) NOMINATIONCOMMITTEE Mr.WangLiFeng Mr.HuangBin(Chairman)(appointedon4March2022) Dr.YanKaShing Mr.